Genentech Herceptin patent litigation
Chiron lawsuit claims Genentech's HER-2 monoclonal antibody Herceptin infringes its recently issued patent No. 6,054,561, which covers monoclonal antibodies that bind selectively to the HER-2 antigen. Chiron said it would be "excited to license the technology, on commercially reasonable terms, to Genentech and others." The lawsuit, filed June 8 in Sacramento federal court, seeks treble damages but does not request an injunction on Genentech's marketing of the breast cancer therapy
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth